PMOS and Dementia Risk May Be Driven by Metabolic Health, Not the Condition Itself

Health & Fitness
15 Nov 2026 • 9:31 AM MYT
PP Health Malaysia
PP Health Malaysia

Making cutting-edge health insights accessible

PMOS and Dementia Risk May Be Driven by Metabolic Health, Not the Condition Itself

A new scientific review has raised important questions about the long-term brain health of people with polyendocrine metabolic ovarian syndrome, or PMOS, formerly called polycystic ovary syndrome.

The evidence does not show that PMOS directly causes Alzheimer’s disease or dementia. It does, however, suggest that metabolic problems often associated with the condition may contribute to cognitive decline over time.

The review, published in the Journal of the Endocrine Society, examined studies on brain structure, cognitive performance, neurodegenerative biomarkers and dementia risk in people with PMOS. Researchers searched medical literature published through 2025, using both PMOS and PCOS terminology.

Its conclusion is cautious. PMOS itself may not be the direct cause of future dementia. Insulin resistance, obesity, type 2 diabetes, high cholesterol, high blood pressure, chronic inflammation and disrupted sleep may be more important explanations for the apparent connection.

That distinction is significant.

PMOS is a complex condition involving hormonal and metabolic changes. It can cause irregular periods, difficulties with ovulation, elevated androgen levels, acne, unwanted hair growth and weight-related concerns.

Symptoms differ widely between individuals. Some people have marked insulin resistance or high cholesterol. Others do not. A diagnosis of PMOS should not be interpreted as a prediction of cognitive impairment or dementia.

Still, the condition can be linked with health issues already known to affect the brain. These include raised blood sugar, abnormal cholesterol levels, cardiovascular disease risk and sleep apnoea. Each may have consequences that extend beyond reproductive health.

The review identified studies suggesting that some people with PMOS show mild differences in cognitive abilities. Areas mentioned included executive function, working memory, processing speed and word recognition. Executive function covers skills such as planning, organising, focusing attention and making decisions.

These changes were generally subtle. They do not mean that a person has dementia. Nor do they prove that such differences will worsen with age. Cognitive performance can be influenced by many factors, including sleep, stress, mood, medication, education, physical activity and general health.

Some imaging studies have also found differences in brain structure or brain activity in people with PMOS. These studies used magnetic resonance imaging, known as MRI, and positron emission tomography, or PET. Researchers have reported variations in grey matter and functional patterns in certain areas of the brain.

Such findings need careful interpretation. Imaging studies can be small. They may involve participants of different ages, with different symptoms, treatments and metabolic profiles. A difference visible on a scan does not necessarily indicate illness, future dementia or reduced day-to-day functioning.

The review also discussed Alzheimer’s-related biomarkers. Alzheimer’s disease is associated with changes involving amyloid-beta and tau proteins, which can accumulate abnormally in the brain. Some studies have identified higher levels of certain related markers among people with PMOS.

However, these results often overlap with the biological changes found in insulin resistance, obesity and type 2 diabetes. The review noted that neurological differences appeared less pronounced when people with PMOS were compared with metabolically healthy control groups. This supports the idea that metabolic risk factors may be driving much of the association.

Insulin resistance may be especially relevant.

Insulin helps regulate blood glucose, though its role extends beyond the pancreas and muscles. The hormone also has functions in the brain, where it supports energy use and cell signalling. The brain requires a substantial and steady supply of energy. When insulin signalling is disrupted, brain cells may not use glucose as effectively.

Scientists are investigating whether this impaired signalling can contribute to memory and thinking difficulties over time. It is one reason type 2 diabetes has been linked with an increased risk of cognitive decline and dementia.

The relationship is not straightforward. Diabetes can affect the brain through several routes. Persistently high blood glucose can damage small blood vessels. Hypertension often occurs alongside diabetes. High cholesterol, inflammation and stroke risk may also increase. These factors can harm brain health independently or together.

For people with PMOS, this means that monitoring metabolic health is not merely about preventing diabetes. It may also be relevant to long-term cardiovascular and cognitive wellbeing.

Obesity was another pathway discussed in the review. Excess body fat, particularly fat stored around the abdomen and internal organs, can increase inflammation and reduce insulin sensitivity. It may also affect blood pressure, cholesterol and sleep quality.

Weight is not a complete measure of health. People of all body sizes can develop metabolic problems, while some people in larger bodies may have normal blood sugar and cardiovascular markers. Even so, when weight-related changes are affecting mobility, sleep, blood pressure or glucose regulation, personalised support can be beneficial.

Dyslipidaemia, or unhealthy levels of fats in the blood, may also contribute to risk. High levels of low-density lipoprotein cholesterol can lead to narrowing of arteries. This process, known as atherosclerosis, can reduce blood flow to the heart and brain. Poor vascular health has been linked to vascular dementia and may worsen the effects of Alzheimer’s disease.

Sleep is another important piece of the picture. Some people with PMOS are more likely to experience poor-quality sleep or obstructive sleep apnoea. Sleep apnoea causes breathing to stop and start repeatedly during the night. It can lead to daytime fatigue, headaches, reduced concentration and increased strain on the heart and blood vessels.

Persistent sleep disruption may also worsen insulin resistance. It can affect mood and memory. Good sleep is not simply a comfort issue; it is part of metabolic and brain health.

The review also highlighted possible roles for inflammation, altered sex hormones and changes in the gut microbiome. Chronic, low-grade inflammation has been associated with both metabolic disease and neurodegeneration. Elevated androgen levels are common in PMOS, although their exact relevance to dementia risk remains uncertain.

Gut dysbiosis, an imbalance in digestive microorganisms, is a fast-moving research area. The gut and brain communicate through immune, hormonal and nerve pathways. Scientists are increasingly studying whether gut health affects inflammation, metabolism and cognition. At present, there is not enough evidence to make specific gut-based recommendations for preventing dementia in people with PMOS.

The strongest message from the review is that correlation should not be mistaken for causation. Many of the available studies are observational. They can show that two factors occur together, but they cannot prove that one causes the other.

There are also gaps in the evidence. Dementia usually develops later in life, while PMOS is often diagnosed during adolescence or early adulthood. Few studies have followed large groups of people with PMOS over several decades. More research is needed to establish whether PMOS independently changes dementia risk once diabetes, obesity, blood pressure and cholesterol are taken into account.

The findings still have practical value. They reinforce the need for comprehensive care. PMOS management should extend beyond menstrual symptoms, fertility concerns and visible signs of androgen excess. It should include regular assessment of blood sugar, cholesterol, blood pressure, weight-related health, sleep and emotional wellbeing.

Exercise remains one of the most useful interventions. Aerobic activities such as brisk walking, cycling, swimming and dancing can improve cardiovascular fitness and insulin sensitivity. Strength training helps maintain muscle mass, supports glucose control and can improve physical function. The best routine is one that is realistic, enjoyable and sustainable.

A Mediterranean-style eating pattern may also support heart and metabolic health. It includes vegetables, fruit, beans, wholegrains, nuts, seeds, olive oil, fish and lean protein. It places less emphasis on highly processed foods, refined carbohydrates, sugary drinks and excessive saturated fat. There is no need for an extreme diet. Consistent habits tend to be more effective than short-term restriction.

Medication may be appropriate for some people. Metformin is often used to improve insulin sensitivity in PMOS. Other treatments may be prescribed for diabetes, cholesterol or high blood pressure. These medicines should be selected according to individual health needs and monitored by a clinician. There is no proof that these treatments specifically prevent dementia in PMOS, but they can improve metabolic and cardiovascular health.

Avoiding smoking, limiting alcohol, sleeping adequately, staying socially connected and keeping the mind active can also support healthy ageing. Reading, learning, community activities, hobbies and regular contact with others may all contribute to cognitive resilience.

The review should not cause unnecessary fear. Having PMOS does not mean a person will develop Alzheimer’s disease. It does underline the importance of recognising and treating modifiable metabolic risks early.

People with PMOS may wish to discuss their individual risk profile with a healthcare professional. Useful questions include whether blood glucose, cholesterol and blood pressure are being checked regularly, whether sleep symptoms need assessment, and what changes could realistically improve long-term health.

Researchers now need larger and longer studies that follow people with PMOS into later adulthood. These studies should account for differences in weight, diabetes status, medication use, ethnicity, healthcare access and lifestyle. They should also examine whether better management of metabolic factors changes cognitive outcomes.

For now, the evidence points towards a practical conclusion: supporting metabolic health may be one of the clearest ways to protect the brain as well as the body.

The post PMOS and Dementia Risk May Be Driven by Metabolic Health, Not the Condition Itself first appeared on PP Health Malaysia (PPHM) | 10POINTS Evidence-Based Health News.

Newswav Malaysia Best News App

Newswav is an online content aggregator and obtains its content from different online sources. The content in the app do not belong to Newswav nor do they reflect the opinions of Newswav and its staff. Your use of this app indicates your understanding and acceptance of this information.

Newswav Sdn. Bhd. (201701008480 (1222645-M)) 2026 All Rights Reserved